Publications by authors named "Yiru Long"

Claim this Profile
A
A Potent Oral Sialylation Inhibitor Augments the Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Jiahui Mou, Runqiu Chen, Zihao Dai, Hao Yang, Feiyashan Suo, Yiru Long

ACS Cent Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-blocking anti-PD-L1 nanobody conjugated to TLR7 agonist mediates macrophage/NK cell-associated antitumor effects.
Chao Hu, Chen Chen, Xiaolu Yu, Zhiying Li, Feng Tang, Yiru Long

Acta Pharm Sin B· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by C-type lectin pathway-mediated tumor associated macrophages repolarizing.
Yongliang Tong, Runqiu Chen, Xinrong Lu, Cuiying Chen, Guiqin Sun, Yiru Long

Int J Biol Macromol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling.
Fang-Lin Li, Long-Hua Gu, Yong-Liang Tong, Run-Qiu Chen, Shi-Yi Chen, Yi-Ru Long

Acta Pharmacol Sin· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GFPBW1, a β-glucan from Grifola frondosa as vaccine adjuvant: APCs activation and maturation.
Xiang He, Jiang-Ling Lu, Wen-Feng Liao, Yi-Ru Long, Xing Zhang

Acta Pharmacol Sin· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards a comprehensive view of the herpes B virus.
Jiangling Lu, Yiru Long, Jianhua Sun, Likun Gong

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Xiao-Min Jia, Yi-Ru Long, Xiao-Lu Yu, Run-Qiu Chen, Li-Kun Gong

Acta Pharmacol Sin· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
Yiru Long, Runqiu Chen, Xiaolu Yu, Yongliang Tong, Xionghua Peng

Cancer Immunol Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Xiaolu Yu, Yiru Long, Binfan Chen, Yongliang Tong, Mengwen Shan

J Immunother Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different Immunoregulation Roles of Activin A Compared With TGF-β.
Fanglin Li, Yiru Long, Xiaolu Yu, Yongliang Tong, Likun Gong

Front Immunol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.
Yiru Long, Xiaolu Yu, Runqiu Chen, Yongliang Tong, Likun Gong

Front Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.
Yiru Long, Jianhua Sun, Tian-Zhang Song, Tingting Liu, Feng Tang, Longfei Ding, Xin-Yan Long

Cell Discov· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis